Astral Systems

We are applying our breakthrough technology to create meaningful solutions to prescient problems today. We are developing innovative system designs to address global challenges such as those in health access and zero carbon energy. A second facility built around a DT MSF reactor is planned for development starting in late Q3, 2023. First demonstrations of medical isotope production are planned for late 2023 or early 2024. Through partnerships with organisations such as the UKAEA, Astral has already provided valuable data using its reactor technologies that will accelerate the development of fusion power. Due to the ultra-compact and modular nature of our systems, we are able to design fusion research facilities built around a plurality or cluster of Astral reactors to maximize neutron flux within a focused test volume. Nuclear medicine is a vital tool used around the world to diagnose and treat life-threatening diseases every day. We aim to provide medical isotope production at the point of care for both diagnostic and therapeutic applications.